First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: Imaging and clinical results of the dessolve i trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries)

JACC: Cardiovascular Interventions

Volumn 6, Issue 10, 2013, Pages 1026-1034

  Ormiston, John ^a,b   Webster, Mark ^b   Stewart, James ^a   Vrolix, Mathias ^c   Whitbourn, Robert ^d   Donohoe, Dennis ^e   Knape, Charlene ^e   Lansky, Alexandra ^f   Attizzani, Guilherme F ^g   Fitzgerald, Peter ^h   Kandzari, David E ⁱ   Wijns, William ^j  

^a Mercy Angiography Unit   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c DEPARTMENT OF CARDIOLOGY   (Belgium)

^d ST VINCENT S HOSPITAL   (Australia)

^e Micell Technologies Inc   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

^h STANFORD UNIVERSITY MEDICAL CENTER   (United States)

ⁱ PIEDMONT HEART INSTITUTE   (United States)

^j CARDIOVASCULAR CENTER   (Belgium)

more..

Author keywords

absorbable polymer; coronary artery disease; coronary stent(s); percutaneous coronary intervention; sirolimus eluting stent(s); stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CHROMIUM; CLOPIDOGREL; COBALT; POLYMER; PRASUGREL; RAPAMYCIN; TICLOPIDINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEALING; HEART INFARCTION; HUMAN; INFLAMMATION; INTRAVASCULAR ULTRASOUND; MALE; MULTICENTER STUDY; NEOINTIMA; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SAFETY; STENOSIS; THERAPY EFFECT; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ABSORBABLE POLYMER; ABSORBABLE POLYMER(S); ABSORBABLE POLYMER-COATED, SIROLIMUS-ELUTING STENT(S); AP; APSES; BARE-METAL STENT(S); BMS; CI; CONFIDENCE INTERVAL; CORONARY ARTERY DISEASE; CORONARY STENT(S); DAPT; DES; DRUG-ELUTING STENT(S); DUAL ANTIPLATELET THERAPY; INCOMPLETE STENT APPOSITION; INTRAVASCULAR ULTRASOUND; ISA; IVUS; LATE LUMEN LOSS; LLL; MACE; MAJOR ADVERSE CARDIAC EVENT(S); MI; MINIMAL LUMEN DIAMETER; MLD; MYOCARDIAL INFARCTION; OCT; OPTICAL COHERENCE TOMOGRAPHY; PERCUTANEOUS CORONARY INTERVENTION; QCA; QUANTITATIVE CORONARY ANGIOGRAPHY; SES; SIROLIMUS-ELUTING STENT; SIROLIMUS-ELUTING STENT(S); ST; STENT THROMBOSIS; TARGET LESION REVASCULARIZATION; TARGET VESSEL REVASCULARIZATION; TLR; TVR;

ABSORBABLE IMPLANTS; ADULT; AGED; AGED, 80 AND OVER; ANGINA, STABLE; ANGINA, UNSTABLE; AUSTRALIA; BELGIUM; CARDIOVASCULAR AGENTS; CHROMIUM ALLOYS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY STENOSIS; CORONARY VESSELS; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEOINTIMA; NEW ZEALAND; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; POLYMERS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; SEVERITY OF ILLNESS INDEX; SIROLIMUS; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84886422051     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2013.05.013     Document Type: Article

References (40)

1. M.-C. Morice, P.W. Serruys, and J.E. Sousa A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization N Engl J Med 346 2002 1773 1780
2. G.W. Stone, S.G. Ellis, D.A. Cox TAXUS-IV Investigators A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 350 2004 221 231
3. C. Indolfi, M. Pavia, and I.F. Angelillo Drug-eluting stents versus bare metal stents in percutaneous coronary interventions (a meta-analysis) Am J Cardiol 95 2005 1146 1152
4. J.R. Nebeker, R. Virmani, and C.L. Bennett Hypersensitivity cases associated with drug-eluting coronary stents. A review of available cases from the Research on Adverse Drug Events and Reports (RADAR) Project J Am Coll Cardiol 47 2006 175 181
5. S.J. Park, S.J. Kang, and R. Virmani In-stent neoatherosclerosis. A final common pathway of late stent failure J Am Coll Cardiol 59 2012 2061 2067
6. A.J. Nordmann, M. Briel, and H.C. Bucher Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis Eur Heart J 27 2006 2784 2814
7. J.A. Ormiston, A. Abizaid, J. Spertus NEVO ResElution-I Investigators Six-month results of the NEVO Res-Elution I (NEVO RES-I) trial: a randomized, multicenter comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberté paclitaxel-eluting stent in de novo native coronary artery lesions Circ Cardiovasc Interv 3 2010 556 564
8. T.A. Ahmed, S.C. Bergheanu, and T. Stijnen Clinical performance of drug-eluting stents with biodegradable polymeric coating: a meta-analysis and systematic review EuroIntervention 7 2011 505 516
9. S. Windecker, P. Serruys, and S. Wandel Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularization (LEADERS): a randomized non-inferiority trial Lancet 378 2008 1940 1948
10. G.G. Stefanini, R.A. Byrne, and P.W. Serruys Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials Eur Heart J 33 2012 1214 1222
11. D.E. Kandzari, C.S. Barker, and M.B. Leon Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents J Am Coll Cardiol Intv 4 2011 1119 1128
12. M. Valgimigli, M. Borghesi, M. Tebaldi, P. Vranckx, G. Parrinello, R. Ferrari PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY Investigators Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A prespecified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) Eur Heart J 34 2013 909 919
13. W.C. Carlyle, J.B. McClain, and A.R. Tzafriri Enhanced drug delivery capabilities from stents coated with absorbable polymer and crystalline drug J Control Release 162 2012 561 567
14. S.G. Ellis, M.G. Vandormael, and M.J. Cowley Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group Circulation 82 1990 1193 1202
15. G.F. Attizzani, H.G. Bezerra, and D. Chamié Serial Evaluation of Vascular Response After Implantation of a New Sirolimus-Eluting Stent With Bioabsorbable Polymer (MISTENT): an optical coherence tomography and histopathological study J Invasive Cardiol 24 2012 560 568
16. N. Gonzalo, H.M. Garcia-Garcia, and P.W. Serruys Reproducibility of quantitative optical coherence tomography for stent analysis EuroIntervention 5 2009 224 232
17. D.E. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
18. J.A. Ormiston, B. Webber, and M.W.I. Webster Stent longitudinal integrity bench insights into a clinical problem J Am Coll Cardiol Intv 4 2011 1310 1317
19. H.Y. Peng, M. Chen, and B. Zheng Long-term effects of novel biodegradable, polymer-coated, sirolimus-eluting stents on neointimal formation in a porcine coronary model Int Heart J 50 2009 811 822
20. M. Pfisterer, H.P. Brunner-La Rocca, P.T. Buser on behalf of BASKET-LATE Investigators Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents J Am Coll Cardiol 48 2006 2584 2591
21. L. Mauri, W.H. Hsieh, and J.M. Massaro Stent thrombosis in randomized clinical trials of drug-eluting stents N Engl J Med 356 2007 1020 1029
22. T.F. Luscher, J. Steffel, and F.R. Eberli Drug-eluting stents and coronary thrombosis: biological mechanisms and clinical implications Circulation 115 2007 1051 1058
23. L.O. Jensen, M. Maeng, and A. Kaltoft Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions J Am Coll Cardiol 50 2007 463 470
24. R. Virmani Evolving DES platforms Circulation 122 2010 A411
25. A. Finn, M. Joner, and G. Nakazawa Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization Circulation 115 2007 2435 2441
26. D.E. Kandzari, M.B. Leon, and J.J. Popma Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial J Am Coll Cardiol 48 2006 2440 2447
27. E. Kedhi, K.S. Joesoef, and E. McFadden Second generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial Lancet 375 2010 201 209
28. A. Gershlick, D.E. Kandzari, M.B. Leon ENDEAVOR Investigators Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients Am J Cardiol 100 2007 45M 55M
29. T. Palmerini, G. Biondi-Zoccai, and D. Della Riva Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis Lancet 379 2012 1393 1402
30. J. Ormiston, and M. Webster Stent thrombosis: has the firestorm been extinguished? Lancet 379 2012 1368 1369
31. L. Räber, L. Wohlwend, and M. Wigger Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial Circulation 123 2011 2819 2828
32. T. Kimura, T. Morimoto, Y. Nakagawa j-Cypher Registry Investigators Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry Circulation 125 2012 584 591
33. G.W. Stone, A. Rizvi, K. Sudhir SPIRIT IV Investigators Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial J Am Coll Cardiol 58 2011 19 25
34. L.O. Jensen, P. Thayssen, H.S. Hansen Scandinavian Organization for Randomized Trials With Clinical Outcome IV (SORT OUT IV) Investigators Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV) Circulation 125 2012 1246 1255
35. G. Guagliumi, V. Sirbu, and G. Musumeci Examination of the in vivo mechanisms of late drug-eluting stent thrombosis: findings from optical coherence tomography and intravascular ultrasound imaging J Am Coll Cardiol Intv 5 2012 12 20
36. G. Nakazawa, A.V. Finn, and M. Vorpahl Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents J Am Coll Cardiol 57 2011 390 398
37. G. Nakazawa, F. Otsuka, and M. Nakano The pathology of neoatherosclerosis in human coronary implants. Bare-metal and drug-eluting stents J Am Coll Cardiol 57 2011 1314 1322
38. G.G. Stefanini, B. Kalesan, and P.W. Serruys Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial Lancet 378 2011 1940 1948
39. E.H. Chistiansen, L.O. Jensen, and P. Thayssen Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomized non-inferiority trial Lancet 381 2013 661 669
40. E.P. Navarese, J. Kubica, and F. Castriota Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials EuroIntervention 7 2011 985 994